Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M, Croyle JA, Noorzad Z, Calagua C, MacDonald TY, Axcrona U, Bogaard M, Axcrona K, Scherr DS, Sanda MG, Johannessen B, Chinnaiyan AM, Elemento O, Skotheim RI, Rubin MA, Barbieri CEet al.(2022) Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci JCI Insight, 7(4) DOI 10.1172/jci.insight.155309, PubMed 35050902
Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich Det al.(2022) Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway J Transl Med, 20(1), 225 DOI 10.1186/s12967-022-03432-5, PubMed 35568909
Kidd SG, Bogaard M, Carm KT, Bakken AC, Maltau AMV, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI(2022) In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis Mol Oncol(in press) DOI 10.1002/1878-0261.13225, PubMed 35574900